Loading...
Market
What will be Terns Pharmaceuticals' stock price at the end of 2024?
2
Resolution / Starting Odds
Less than $20 • 25%
$20 to $30 • 25%
$30 to $40 • 25%
More than $40 • 25%
Stock market data from sources like Yahoo Finance, Google Finance
Story
Terns Pharmaceuticals' Weight-Loss Drug Shows 4.9% Reduction, Stock Surges
Sep 9, 2024, 11:33 AM
Terns Pharmaceuticals has announced positive Phase 1 clinical trial results for its once-daily oral GLP-1R agonist, TERN-601, aimed at treating obesity. The trial demonstrated a statistically significant mean weight loss of up to 5.5% over 28 days, with a placebo-adjusted weight loss of 4.9%. The study also reported an absence of treatment-related dose interruptions, reductions, or discontinuations, despite aggressive titration to high doses, and mostly mild AEs, suggesting improved tolerability with slower titration in future studies. Following the announcement, Terns Pharmaceuticals' stock surged, rising 10% in regular trading and 31% in premarket trading.
View original story
Similar markets
Above $25 • 25%
$20 - $25 • 25%
$15 - $20 • 25%
Below $15 • 25%
Below $25 • 25%
$25 - $50 • 25%
$50 - $75 • 25%
Above $75 • 25%
Below $2 • 25%
$2 to $5 • 25%
Above $10 • 25%
Below $5 • 25%
$5 to $10 • 25%
$10 to $15 • 25%
Above $15 • 25%
Above $25 • 25%
$20-$25 • 25%
$15-$20 • 25%
Below $15 • 25%
Below $5 • 25%
$5 to $7 • 25%
$7 to $9 • 25%
Above $9 • 25%
Increase by 20% or more • 25%
Increase by less than 20% • 25%
Remain about the same • 25%
Decrease • 25%
Above $10 • 25%
$8 to $10 • 25%
$6 to $8 • 25%
Below $6 • 25%
Above $100 • 25%
$75 to $100 • 25%
$50 to $75 • 25%
Below $50 • 25%
Below $60 • 25%
$60-$70 • 25%
$70-$80 • 25%
Above $80 • 25%
Less than 50% • 25%
50% to 100% • 25%
100% to 200% • 25%
More than 200% • 25%
Increase by 0-10% • 25%
Increase by 10-20% • 25%
Increase by more than 20% • 25%
Decrease or no change • 25%